Mounjaro shows strong signs of being beneficial for heart health across several measures, though it doesn’t yet carry an official FDA approval specifically for reducing cardiovascular risk. The drug lowers blood pressure, improves cholesterol and triglyceride levels, reduces inflammation, and in one major trial cut the risk of heart failure events by nearly 60% in a specific group of patients. Here’s what the evidence actually shows.
Heart Failure: The Strongest Evidence So Far
The most compelling heart data for tirzepatide (the active ingredient in Mounjaro and Zepbound) comes from the SUMMIT trial, which studied patients who had a common type of heart failure called HFpEF, where the heart pumps normally but doesn’t relax and fill properly, combined with obesity. Tirzepatide reduced the combined risk of cardiovascular death or worsening heart failure by 38% compared to placebo. That result was driven almost entirely by fewer heart failure events requiring hospitalization or urgent care, where the risk dropped by 59%.
Beyond fewer emergencies, patients on tirzepatide felt meaningfully better. Heart failure symptoms and physical limitations improved significantly over 52 weeks, with nearly half of treated patients hitting a threshold that represents a real, noticeable change in daily quality of life, compared to about 35% on placebo. For people living with the breathlessness, fatigue, and swelling that define this condition, those improvements translate to doing more with less struggle.
A 2025 scientific statement from the American College of Cardiology now recognizes tirzepatide alongside semaglutide as medications that reduce heart failure events in people with obesity and HFpEF, including those without diabetes. One important caveat: the safety profile in people with heart failure where the heart muscle is weakened (reduced ejection fraction) is less established.
Blood Pressure Drops Significantly
High blood pressure is the single largest contributor to heart disease worldwide, so any meaningful reduction matters. In the SURMOUNT-1 trial, tirzepatide lowered systolic blood pressure (the top number) by an average of 8.1 mmHg over 72 weeks, compared to just 1.3 mmHg with placebo. That’s a net difference of about 6.8 mmHg. Diastolic pressure (the bottom number) dropped by 5.3 mmHg versus 1.0 mmHg on placebo, a net difference of 4.2 mmHg.
To put that in perspective, a sustained 5 mmHg reduction in systolic blood pressure is associated with roughly a 10% lower risk of major cardiovascular events at the population level. A 6.8 mmHg drop is clinically significant and comparable to what many common blood pressure medications achieve. An FDA-mandated substudy of 600 patients using 24-hour ambulatory monitoring confirmed these reductions and concluded they “suggest potential cardiovascular benefits.”
Cholesterol and Triglycerides Improve
Tirzepatide improves your lipid profile in a dose-dependent way, meaning higher doses produce larger effects. A systematic review and meta-analysis of randomized controlled trials found the following percentage reductions from baseline:
- Triglycerides: 13% reduction at 5 mg, 18% at 10 mg, and 22% at 15 mg
- LDL cholesterol: 6% reduction at 5 mg, 6% at 10 mg, and 8% at 15 mg
The triglyceride reductions are particularly notable. Elevated triglycerides are an independent risk factor for heart disease, and a 22% drop at the highest dose rivals what some dedicated lipid-lowering therapies achieve. The LDL reductions are more modest, so tirzepatide wouldn’t replace a statin for someone who needs significant LDL lowering, but it adds to the overall cardiovascular picture.
Inflammation Markers Drop Substantially
Chronic, low-grade inflammation plays a central role in how plaque builds up in arteries and eventually ruptures to cause heart attacks and strokes. High-sensitivity C-reactive protein (hsCRP) is one of the best-studied markers of this process. In a post-hoc analysis of the SURPASS-4 trial involving patients with type 2 diabetes and high cardiovascular risk, tirzepatide reduced hsCRP by 38% at the 5 mg dose, 44% at 10 mg, and 48% at 15 mg over 52 weeks. The comparison group showed essentially no change, dropping just 0.6%.
These are large reductions. While hsCRP is a marker rather than a direct cause, lowering systemic inflammation by this magnitude suggests tirzepatide is doing more than just helping people lose weight. It appears to be shifting the underlying biology that drives cardiovascular disease.
Kidney Function and Heart Risk
Kidney disease and heart disease are deeply intertwined. Declining kidney function raises cardiovascular risk substantially, and heart failure accelerates kidney damage. Data from the SUMMIT trial showed that tirzepatide improved kidney function markers over time, and patients who already had chronic kidney disease saw a numerically larger absolute benefit: 3.6 heart failure events prevented per 100 patients treated per year, compared to 1.6 events prevented per 100 patients without kidney disease. In other words, those at highest cardiorenal risk may have the most to gain.
One Trade-Off: A Slight Heart Rate Increase
Tirzepatide does raise resting heart rate by about 2 to 5 beats per minute, depending on the dose. This is consistent with other drugs in the GLP-1 class and was specifically monitored in an FDA-required substudy. The increase falls within the expected range and, based on the available evidence, does not appear to offset the blood pressure and other cardiovascular benefits. Still, for people who already have a fast resting heart rate or certain heart rhythm conditions, it’s something worth discussing with a cardiologist.
No Formal Heart Approval Yet
Despite the accumulating evidence, tirzepatide does not currently have FDA approval for cardiovascular risk reduction. Mounjaro is approved for blood sugar management in type 2 diabetes, and Zepbound is approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. The FDA noted in its Zepbound approval that losing 5% to 10% of body weight is associated with reduced cardiovascular risk, but that’s different from a specific heart indication.
The SURPASS-CVOT trial, which directly compares tirzepatide to another diabetes drug for major adverse cardiovascular events like heart attacks and strokes, is expected to report results in 2025. Early signals from the smaller SURPASS-4 trial were encouraging, showing a 50% reduction in major cardiovascular events, but with only 11 events total, the study was too small to draw firm conclusions. The larger trial should provide the definitive answer on whether tirzepatide earns a formal cardiovascular indication, potentially putting it on the same footing as semaglutide (Ozempic/Wegovy), which already has one.
What the current evidence shows is a drug that improves nearly every measurable cardiovascular risk factor: blood pressure, triglycerides, LDL cholesterol, inflammatory markers, kidney function, and heart failure outcomes. Whether that translates into fewer heart attacks and strokes at a population level is the remaining question, and one that should be answered soon.